Frostyyy的个人主页 - 老虎社区

Frostyyy

暂无个人介绍

IP属地：未知

10关注

3粉丝

0主题

0勋章

2021-12-07

EV to the moon

抱歉，原内容已删除

2021-12-02

Not the time yet

抱歉，原内容已删除

2021-11-16

Pls drop so that i can buy more

抱歉，原内容已删除

2021-11-03

To the moon!!

Some meme stocks skyrocketed in premarket trading

2021-11-02

Go go go!!!

Novavax shares jumped another 4.4% in premarket trading

2021-10-22

$AMD(AMD)$ up up up!!!

2021-10-20

Gg overpromise again

Novavax plunged over 20% in premarket trading

2021-10-19

Very good

抱歉，原内容已删除

2021-10-06

But why stock price still drop??

抱歉，原内容已删除

2021-10-06

why sell???

抱歉，原内容已删除

2021-08-16

loving the reds

抱歉，原内容已删除

2021-06-18

Nice

Toplines Before US Market Open on Friday

2021-06-18

Team red!!

抱歉，原内容已删除

2021-06-16

Sick. Need more dips

Toplines Before US Market Open on Wednesday

2021-06-16

Wow

抱歉，原内容已删除

2021-06-15

Nice

抱歉，原内容已删除

2021-06-15

Good to dip your toes into a little bit of crypto.

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3581131361771943","uuid":"3581131361771943","gmtCreate":1618276998852,"gmtModify":1618276998852,"name":"Frostyyy","pinyin":"frostyyy","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":10,"tweetSize":17,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.02","exceedPercentage":"80.22%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":606853487,"gmtCreate":1638861086065,"gmtModify":1638861086179,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"EV to the moon","listText":"EV to the moon","text":"EV to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606853487","repostId":"2189682681","repostType":4,"isVote":1,"tweetType":1,"viewCount":2480,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603619690,"gmtCreate":1638404643257,"gmtModify":1638404643467,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Not the time yet","listText":"Not the time yet","text":"Not the time yet","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603619690","repostId":"2188690505","repostType":4,"isVote":1,"tweetType":1,"viewCount":2741,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871185699,"gmtCreate":1637037132655,"gmtModify":1637037302349,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Pls drop so that i can buy more","listText":"Pls drop so that i can buy more","text":"Pls drop so that i can buy more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/871185699","repostId":"1160740007","repostType":4,"isVote":1,"tweetType":1,"viewCount":2023,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841543109,"gmtCreate":1635928603322,"gmtModify":1635928603322,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"To the moon!!&nbsp;","listText":"To the moon!!&nbsp;","text":"To the moon!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/841543109","repostId":"1178338626","repostType":4,"repost":{"id":"1178338626","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635928227,"share":"https://www.laohu8.com/m/news/1178338626?lang=&edition=full","pubTime":"2021-11-03 16:30","market":"us","language":"en","title":"Some meme stocks skyrocketed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1178338626","media":"Tiger Newspress","summary":"Some meme stocks skyrocketed in premarket trading.Bed Bath & Beyond,R.R. Donnelley & Sons,Naked Bran","content":"<p>Some meme stocks skyrocketed in premarket trading.Bed Bath &amp; Beyond,R.R. Donnelley &amp; Sons,Naked Brand,Koss,Express,AMC,GameStop&nbsp;and&nbsp;BlackBerry&nbsp;soared between 4% and 62%.</p>\n<p><img src=\"https://static.tigerbbs.com/b016995062645d8011221cff13a86966\" tg-width=\"404\" tg-height=\"486\" referrerpolicy=\"no-referrer\"></p>\n<p><a href=\"https://laohu8.com/NW/1113177921\" target=\"_blank\">Bed Bath &amp; Beyond</a>,the home-goods retailer announced news that likely fueled a so-called short squeeze, where hedge funds that had bet against the stock were forced to buy back their shares to cut losses.</p>\n<p>Commercial-printing company&nbsp;R.R. Donnelley &amp; Sons&nbsp;Co.&nbsp;is nearing a deal to sell itself to a private-equity firm for just over $2 billion including debt, according to people familiar with the matter.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some meme stocks skyrocketed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome meme stocks skyrocketed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-03 16:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Some meme stocks skyrocketed in premarket trading.Bed Bath &amp; Beyond,R.R. Donnelley &amp; Sons,Naked Brand,Koss,Express,AMC,GameStop&nbsp;and&nbsp;BlackBerry&nbsp;soared between 4% and 62%.</p>\n<p><img src=\"https://static.tigerbbs.com/b016995062645d8011221cff13a86966\" tg-width=\"404\" tg-height=\"486\" referrerpolicy=\"no-referrer\"></p>\n<p><a href=\"https://laohu8.com/NW/1113177921\" target=\"_blank\">Bed Bath &amp; Beyond</a>,the home-goods retailer announced news that likely fueled a so-called short squeeze, where hedge funds that had bet against the stock were forced to buy back their shares to cut losses.</p>\n<p>Commercial-printing company&nbsp;R.R. Donnelley &amp; Sons&nbsp;Co.&nbsp;is nearing a deal to sell itself to a private-equity firm for just over $2 billion including debt, according to people familiar with the matter.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178338626","content_text":"Some meme stocks skyrocketed in premarket trading.Bed Bath & Beyond,R.R. Donnelley & Sons,Naked Brand,Koss,Express,AMC,GameStop and BlackBerry soared between 4% and 62%.\n\nBed Bath & Beyond,the home-goods retailer announced news that likely fueled a so-called short squeeze, where hedge funds that had bet against the stock were forced to buy back their shares to cut losses.\nCommercial-printing company R.R. Donnelley & Sons Co. is nearing a deal to sell itself to a private-equity firm for just over $2 billion including debt, according to people familiar with the matter.","news_type":1,"symbols_score_info":{"AMC":0.9,"BB":0.9,"BBBY":0.9,"EXPR":0.9,"GME":0.9,"KOSS":0.9,"NAKD":0.9,"RRD":0.9}},"isVote":1,"tweetType":1,"viewCount":1487,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843581898,"gmtCreate":1635841643487,"gmtModify":1635841646978,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Go go go!!!&nbsp;","listText":"Go go go!!!&nbsp;","text":"Go go go!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/843581898","repostId":"1146954113","repostType":2,"repost":{"id":"1146954113","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635841327,"share":"https://www.laohu8.com/m/news/1146954113?lang=&edition=full","pubTime":"2021-11-02 16:22","market":"us","language":"en","title":"Novavax shares jumped another 4.4% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1146954113","media":"Tiger Newspress","summary":"Novavax shares jumped another 4.4% in premarket trading Tuesday after rising nearly 16% yesterday as","content":"<p>Novavax shares jumped another 4.4% in premarket trading&nbsp;Tuesday&nbsp;after rising nearly 16% yesterday&nbsp;as&nbsp;Novavax COVID-19 vaccine got first authorization; expected more within weeks.</p>\n<p><img src=\"https://static.tigerbbs.com/93777ff8ed669db1e3ea1516ae6b0f1f\" tg-width=\"849\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>Novavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within “weeks,” its chief executive told Reuters, after the shot on Monday received its first emergency use authorization (EUA) from Indonesia.</p>\n<p>The company also said it had filed an application for emergency use of the vaccine to Canada and the European Medicines Agency.</p>\n<p>For Indonesia, the shot will be manufactured by the world’s largest vaccine manufacturer, Serum Institute in India (SII), and sold under the Indian company’s brand name, Covovax. Novavax said initial shipments into Indonesia are expected to begin imminently.</p>\n<p>The World Health Organization (WHO) is also reviewing Novavax’s regulatory filing and the U.S. drugmaker expects that review to be resolved in the coming weeks, Chief Executive Stanley Erck told Reuters in a phone interview on Monday.</p>\n<p>A green light from the WHO would set the stage for Novavax to begin shipping doses to the COVAX program that supplies shots to low-income countries. Novavax and SII have together committed to provide more than 1.1 billion doses to COVAX, which is co-led by the WHO.</p>\n<p>“I think we’ll get some doses to COVAX this year,” Erck said. “But I think (Novavax is) going to really start being able to ship large quantity to COVAX in the first quarter” of 2022.</p>\n<p>Erck said Novavax has resolved all of its manufacturing challenges and does not expect regulators to have any further concerns about its production processes.</p>\n<p>He said Novavax is “in dialogue with the U.S. FDA and ... we expect a full submission within the next several weeks.”</p>\n<p>Novavax had delayed filing for U.S. approval, and Politico reported last month that the company faced production and quality problems.</p>\n<p>SII is authorized to make the Novavax vaccine and the U.S. company said it will apply for regulatory authorization for other facilities, such as its plant in the Czech republic, in the coming weeks.</p>\n<p>Indonesia is slated to receive 20 million doses of the protein-based vaccine this year, according to the government.</p>\n<p>Penny Lukito, chief of the National Agency for Drug and Food Control of Indonesia, did not immediately respond to a Reuters request for comment.</p>\n<p>Novavax has so far applied for EUA in various countries, including the UK, Australia, India and the Philippines.</p>\n<p>“It will be weeks, not months, for them to review” Novavax’s regulatory submissions and potentially clear the shot for use, Erck said.</p>\n<p>The company, along with Japanese partner Takeda Pharmaceutical Co, said on Friday it was preparing to seek regulatory approval for a rollout in Japan early next year.</p>\n<p>The Novavax shot was shown to be more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based trial.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax shares jumped another 4.4% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax shares jumped another 4.4% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-02 16:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novavax shares jumped another 4.4% in premarket trading&nbsp;Tuesday&nbsp;after rising nearly 16% yesterday&nbsp;as&nbsp;Novavax COVID-19 vaccine got first authorization; expected more within weeks.</p>\n<p><img src=\"https://static.tigerbbs.com/93777ff8ed669db1e3ea1516ae6b0f1f\" tg-width=\"849\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>Novavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within “weeks,” its chief executive told Reuters, after the shot on Monday received its first emergency use authorization (EUA) from Indonesia.</p>\n<p>The company also said it had filed an application for emergency use of the vaccine to Canada and the European Medicines Agency.</p>\n<p>For Indonesia, the shot will be manufactured by the world’s largest vaccine manufacturer, Serum Institute in India (SII), and sold under the Indian company’s brand name, Covovax. Novavax said initial shipments into Indonesia are expected to begin imminently.</p>\n<p>The World Health Organization (WHO) is also reviewing Novavax’s regulatory filing and the U.S. drugmaker expects that review to be resolved in the coming weeks, Chief Executive Stanley Erck told Reuters in a phone interview on Monday.</p>\n<p>A green light from the WHO would set the stage for Novavax to begin shipping doses to the COVAX program that supplies shots to low-income countries. Novavax and SII have together committed to provide more than 1.1 billion doses to COVAX, which is co-led by the WHO.</p>\n<p>“I think we’ll get some doses to COVAX this year,” Erck said. “But I think (Novavax is) going to really start being able to ship large quantity to COVAX in the first quarter” of 2022.</p>\n<p>Erck said Novavax has resolved all of its manufacturing challenges and does not expect regulators to have any further concerns about its production processes.</p>\n<p>He said Novavax is “in dialogue with the U.S. FDA and ... we expect a full submission within the next several weeks.”</p>\n<p>Novavax had delayed filing for U.S. approval, and Politico reported last month that the company faced production and quality problems.</p>\n<p>SII is authorized to make the Novavax vaccine and the U.S. company said it will apply for regulatory authorization for other facilities, such as its plant in the Czech republic, in the coming weeks.</p>\n<p>Indonesia is slated to receive 20 million doses of the protein-based vaccine this year, according to the government.</p>\n<p>Penny Lukito, chief of the National Agency for Drug and Food Control of Indonesia, did not immediately respond to a Reuters request for comment.</p>\n<p>Novavax has so far applied for EUA in various countries, including the UK, Australia, India and the Philippines.</p>\n<p>“It will be weeks, not months, for them to review” Novavax’s regulatory submissions and potentially clear the shot for use, Erck said.</p>\n<p>The company, along with Japanese partner Takeda Pharmaceutical Co, said on Friday it was preparing to seek regulatory approval for a rollout in Japan early next year.</p>\n<p>The Novavax shot was shown to be more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based trial.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146954113","content_text":"Novavax shares jumped another 4.4% in premarket trading Tuesday after rising nearly 16% yesterday as Novavax COVID-19 vaccine got first authorization; expected more within weeks.\n\nNovavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within “weeks,” its chief executive told Reuters, after the shot on Monday received its first emergency use authorization (EUA) from Indonesia.\nThe company also said it had filed an application for emergency use of the vaccine to Canada and the European Medicines Agency.\nFor Indonesia, the shot will be manufactured by the world’s largest vaccine manufacturer, Serum Institute in India (SII), and sold under the Indian company’s brand name, Covovax. Novavax said initial shipments into Indonesia are expected to begin imminently.\nThe World Health Organization (WHO) is also reviewing Novavax’s regulatory filing and the U.S. drugmaker expects that review to be resolved in the coming weeks, Chief Executive Stanley Erck told Reuters in a phone interview on Monday.\nA green light from the WHO would set the stage for Novavax to begin shipping doses to the COVAX program that supplies shots to low-income countries. Novavax and SII have together committed to provide more than 1.1 billion doses to COVAX, which is co-led by the WHO.\n“I think we’ll get some doses to COVAX this year,” Erck said. “But I think (Novavax is) going to really start being able to ship large quantity to COVAX in the first quarter” of 2022.\nErck said Novavax has resolved all of its manufacturing challenges and does not expect regulators to have any further concerns about its production processes.\nHe said Novavax is “in dialogue with the U.S. FDA and ... we expect a full submission within the next several weeks.”\nNovavax had delayed filing for U.S. approval, and Politico reported last month that the company faced production and quality problems.\nSII is authorized to make the Novavax vaccine and the U.S. company said it will apply for regulatory authorization for other facilities, such as its plant in the Czech republic, in the coming weeks.\nIndonesia is slated to receive 20 million doses of the protein-based vaccine this year, according to the government.\nPenny Lukito, chief of the National Agency for Drug and Food Control of Indonesia, did not immediately respond to a Reuters request for comment.\nNovavax has so far applied for EUA in various countries, including the UK, Australia, India and the Philippines.\n“It will be weeks, not months, for them to review” Novavax’s regulatory submissions and potentially clear the shot for use, Erck said.\nThe company, along with Japanese partner Takeda Pharmaceutical Co, said on Friday it was preparing to seek regulatory approval for a rollout in Japan early next year.\nThe Novavax shot was shown to be more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based trial.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1850,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":851838102,"gmtCreate":1634890474595,"gmtModify":1634890474595,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMD\">$AMD(AMD)$</a>&nbsp;up up up!!!&nbsp;","listText":"<a href=\"https://laohu8.com/S/AMD\">$AMD(AMD)$</a>&nbsp;up up up!!!&nbsp;","text":"$AMD(AMD)$ up up up!!!","images":[{"img":"https://static.tigerbbs.com/2da1478496dda3d23161f71934bb6c2b","width":"1080","height":"2375"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/851838102","isVote":1,"tweetType":1,"viewCount":1724,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":859499264,"gmtCreate":1634718770094,"gmtModify":1634721067878,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Gg&nbsp;overpromise again","listText":"Gg&nbsp;overpromise again","text":"Gg overpromise again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859499264","repostId":"1174375951","repostType":2,"repost":{"id":"1174375951","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634717661,"share":"https://www.laohu8.com/m/news/1174375951?lang=&edition=full","pubTime":"2021-10-20 16:14","market":"us","language":"en","title":"Novavax plunged over 20% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1174375951","media":"Tiger Newspress","summary":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the pr","content":"<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p>\n<p><img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p>\n<p>But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p>\n<p>The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p>\n<p>The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p>\n<p>Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p>\n<p>The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p>\n<p>COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p>\n<p>“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p>\n<p>The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p>\n<p>Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p>\n<p>In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p>\n<p>“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p>\n<p>The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p>\n<p>But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p>\n<p>Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p>\n<p>Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p>\n<p>The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p>\n<p>That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p>\n<p>Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p>\n<p>J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p>\n<p>“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p>\n<p>Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p>\n<p>Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p>\n<p>The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p>\n<p>But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p>\n<p>In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p>\n<p>“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p>\n<p>Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p>\n<p>Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p>\n<p>“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p>\n<p>U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p>\n<p>And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p>\n<p>Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p>\n<p>“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax plunged over 20% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax plunged over 20% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-20 16:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p>\n<p><img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p>\n<p>But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p>\n<p>The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p>\n<p>The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p>\n<p>Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p>\n<p>The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p>\n<p>COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p>\n<p>“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p>\n<p>The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p>\n<p>Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p>\n<p>In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p>\n<p>“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p>\n<p>The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p>\n<p>But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p>\n<p>Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p>\n<p>Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p>\n<p>The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p>\n<p>That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p>\n<p>Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p>\n<p>J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p>\n<p>“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p>\n<p>Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p>\n<p>Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p>\n<p>The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p>\n<p>But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p>\n<p>In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p>\n<p>“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p>\n<p>Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p>\n<p>Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p>\n<p>“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p>\n<p>U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p>\n<p>And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p>\n<p>Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p>\n<p>“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174375951","content_text":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.\nThe world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.\nBut the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.\nThe delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.\nThe U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.\nAlthough Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.\nThe Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, one of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.\nCOVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.\n“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the Duke Global Health Innovation Center.\nThe global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.\nBetween Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.\nIn a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.\n“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.\nThe White House and the Department of Health and Human Services did not respond to multiple requests for comment.\nBut three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.\nNovavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.\nUnlike Pfizer and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.\nThe revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.\nThat includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.\nNovavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson & Johnsonhalted work at a Baltimore facilityrun by contract manufacturer Emergent BioSolutions after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.\nJ&J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.\n“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”\nUnlike Johnson & Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.\nYet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.\nThe contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.\nBut even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.\nIn particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.\n“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”\nTaylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.\nCompany executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.\n“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”\nU.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&J’s vaccine at the Emergent plant earlier this year, those people said.\nAnd even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.\nSeveral vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.\n“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1506,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850281587,"gmtCreate":1634602242348,"gmtModify":1634602242420,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Very good","listText":"Very good","text":"Very good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850281587","repostId":"1114416896","repostType":4,"isVote":1,"tweetType":1,"viewCount":1488,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829410404,"gmtCreate":1633532533184,"gmtModify":1633532533259,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"But why stock price still drop??&nbsp;","listText":"But why stock price still drop??&nbsp;","text":"But why stock price still drop??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829410404","repostId":"1169679917","repostType":2,"isVote":1,"tweetType":1,"viewCount":1501,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829404697,"gmtCreate":1633530962458,"gmtModify":1633530962530,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"why sell???","listText":"why sell???","text":"why sell???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829404697","repostId":"1126696993","repostType":2,"isVote":1,"tweetType":1,"viewCount":1775,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":839362705,"gmtCreate":1629122847907,"gmtModify":1633687233567,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"loving the reds","listText":"loving the reds","text":"loving the reds","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/839362705","repostId":"1133200546","repostType":4,"isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166466282,"gmtCreate":1624023123946,"gmtModify":1634023985172,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166466282","repostId":"1147049745","repostType":4,"repost":{"id":"1147049745","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624018214,"share":"https://www.laohu8.com/m/news/1147049745?lang=&edition=full","pubTime":"2021-06-18 20:10","market":"us","language":"en","title":"Toplines Before US Market Open on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1147049745","media":"Tiger Newspress","summary":"U.S. stock futures fell on Friday as the S&P 500 and the Dow Jones Industrial Average are on pace to","content":"<p>U.S. stock futures fell on Friday as the S&amp;P 500 and the Dow Jones Industrial Average are on pace to post a losing week after the Federal Reserve's latest policy update.</p>\n<p>At 8:05 a.m. ET, Dow E-minis were down 153 points, or 0.45%, S&amp;P 500 E-minis were down 14.75 points, or 0.35% and Nasdaq 100 E-minis fell 18.5 points, or 0.13%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/25234fe10c0fe8a9e73f2cec66447216\" tg-width=\"1003\" tg-height=\"316\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:05</span></p>\n<p>The blue-chip Dow has lost 1.9% week to date, on pace for its worst week since January. The S&amp;P 500 has fallen 0.6%. But the Nasdaq has gained 0.65% on the week.</p>\n<p>The decline in stocks came amid a drastic flattening of the so-called Treasury yield curve&nbsp;where the yields of shorter-duration Treasurys, like the&nbsp;2-year note, rose, while longer duration yields, such as the benchmark 10-year fell.&nbsp;The retreat in long-dated bonds reflects less optimism toward the economic growth, while the jump in short-end yields shows the expectations of the Fed raising rates.</p>\n<p>The central bank's hawkish pivot on Wednesday&nbsp;caused volatile stock and bond market moves. Fed officials added two rate hikes to their 2023 forecast and increased their inflation projection for the year, while Fed Chairman Jerome Powell said officials have discussed tapering bond buying and would at some point begin slowing the asset purchases.</p>\n<p>Friday also coincides with the quarterly \"quadruple witching\" where options and futures on indexes and equities expire. Many expect trading to be more volatile in light of this event.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><b>Adobe(ADBE) </b>– Adobe reported quarterly profit of $3.03 per share, 21 cents a share above estimates. The software company's revenue also topped Wall Street forecasts and Adobe gave stronger-than-expected current-quarter guidance. Its shares rose 3.1% in premarket trading.</p>\n<p><b>Smith &amp; Wesson(SWBI) </b>– Smith &amp; Wesson reported better-than-expected profit and sales for its latest quarter, as the gun maker's sales surged 67% compared to the same quarter a year earlier. The company notes that its shipments jumped 70% compared to overall industry growth of 42%. Shares rallied 4.7% in premarket trading.</p>\n<p><b>Orphazyme(ORPH)</b> – Orphazyme plunged 52.6% in the premarket after the Food and Drug Administration rejected its experimental treatment for a genetic disorder known as Niemann-Pick disease type C. The Denmark-based biotech company had seen volatile trading in its shares in recent days after it picked up social media attention, falling 10.2% Thursday after a more than 61% surge Wednesday.</p>\n<p><b>Delta Air Lines(DAL)</b> – The stock added 1.1% in the premarket following a double upgrade at Wolfe Research to \"outperform\" from \"underperform.\" Wolfe said it sees business travel benefiting from pent-up demand later this summer, although it doesn't think it will return to pre-Covid levels.</p>\n<p><b>Manchester United(MANU) </b>– Manchester United lost $30.2 million for the first three months of this year, due largely to the absence of fans at its games because of the coronavirus pandemic. All of the team's 2020-21 season games were played without spectators.</p>\n<p><b>ArcelorMittal(MT) </b>– ArcelorMittal sold its remaining 38.2 million shares of steel producerCleveland-Cliffs(CLF). The mining company will use the proceeds to fund a $750 million share buyback. Arcelor-Mittal rose 1% in premarket action, while Cleveland-Cliffs added 0.3%.</p>\n<p><b>Carnival(CCL) </b>– The cruise line operator disclosed a March data breach that may have exposed personal information of customers of its Carnival, Holland America and Princess brands. It did not disclose how many may have been affected.</p>\n<p><b>Fox Corp.(FOXA) </b>– Fox increased its stock repurchase program by $2 billion to a total of $4 billion, helping to send its shares higher by 2.8% in the premarket.</p>\n<p><b>Pilgrim's Pride(PPC) </b>– Pilgrim's Pride expanded its prepared foods and branded products business by purchasing Kerry Group's Meats and Meals business. The poultry producer will pay the Ireland-based company about $947 million for that unit.</p>\n<p><b>Hasbro(HAS),Mattel(MAT) </b>– The toymakers are on watch following a New York Post report warning of a potential toy shortage this coming holiday season. The paper said thousands of toys ready for shipment remain stockpiled in China due to the lack of shipping containers available for export.</p>\n<p><b>Biogen(BIIB)</b> – The drugmaker's stock was upgraded to \"overweight\" from \"neutral\" at Piper Sandler, which cites a number of factors including the likelihood that doctors will prescribe Biogen's newly approved Alzheimer's drug Aduhelm. Biogen shares rose 1.7% in the premarket.</p>\n<p><b>Citigroup(C) </b>– The bank's stock remains on watch after declining for the past 11 consecutive trading days, losing 14% over that time.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-18 20:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stock futures fell on Friday as the S&amp;P 500 and the Dow Jones Industrial Average are on pace to post a losing week after the Federal Reserve's latest policy update.</p>\n<p>At 8:05 a.m. ET, Dow E-minis were down 153 points, or 0.45%, S&amp;P 500 E-minis were down 14.75 points, or 0.35% and Nasdaq 100 E-minis fell 18.5 points, or 0.13%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/25234fe10c0fe8a9e73f2cec66447216\" tg-width=\"1003\" tg-height=\"316\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:05</span></p>\n<p>The blue-chip Dow has lost 1.9% week to date, on pace for its worst week since January. The S&amp;P 500 has fallen 0.6%. But the Nasdaq has gained 0.65% on the week.</p>\n<p>The decline in stocks came amid a drastic flattening of the so-called Treasury yield curve&nbsp;where the yields of shorter-duration Treasurys, like the&nbsp;2-year note, rose, while longer duration yields, such as the benchmark 10-year fell.&nbsp;The retreat in long-dated bonds reflects less optimism toward the economic growth, while the jump in short-end yields shows the expectations of the Fed raising rates.</p>\n<p>The central bank's hawkish pivot on Wednesday&nbsp;caused volatile stock and bond market moves. Fed officials added two rate hikes to their 2023 forecast and increased their inflation projection for the year, while Fed Chairman Jerome Powell said officials have discussed tapering bond buying and would at some point begin slowing the asset purchases.</p>\n<p>Friday also coincides with the quarterly \"quadruple witching\" where options and futures on indexes and equities expire. Many expect trading to be more volatile in light of this event.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><b>Adobe(ADBE) </b>– Adobe reported quarterly profit of $3.03 per share, 21 cents a share above estimates. The software company's revenue also topped Wall Street forecasts and Adobe gave stronger-than-expected current-quarter guidance. Its shares rose 3.1% in premarket trading.</p>\n<p><b>Smith &amp; Wesson(SWBI) </b>– Smith &amp; Wesson reported better-than-expected profit and sales for its latest quarter, as the gun maker's sales surged 67% compared to the same quarter a year earlier. The company notes that its shipments jumped 70% compared to overall industry growth of 42%. Shares rallied 4.7% in premarket trading.</p>\n<p><b>Orphazyme(ORPH)</b> – Orphazyme plunged 52.6% in the premarket after the Food and Drug Administration rejected its experimental treatment for a genetic disorder known as Niemann-Pick disease type C. The Denmark-based biotech company had seen volatile trading in its shares in recent days after it picked up social media attention, falling 10.2% Thursday after a more than 61% surge Wednesday.</p>\n<p><b>Delta Air Lines(DAL)</b> – The stock added 1.1% in the premarket following a double upgrade at Wolfe Research to \"outperform\" from \"underperform.\" Wolfe said it sees business travel benefiting from pent-up demand later this summer, although it doesn't think it will return to pre-Covid levels.</p>\n<p><b>Manchester United(MANU) </b>– Manchester United lost $30.2 million for the first three months of this year, due largely to the absence of fans at its games because of the coronavirus pandemic. All of the team's 2020-21 season games were played without spectators.</p>\n<p><b>ArcelorMittal(MT) </b>– ArcelorMittal sold its remaining 38.2 million shares of steel producerCleveland-Cliffs(CLF). The mining company will use the proceeds to fund a $750 million share buyback. Arcelor-Mittal rose 1% in premarket action, while Cleveland-Cliffs added 0.3%.</p>\n<p><b>Carnival(CCL) </b>– The cruise line operator disclosed a March data breach that may have exposed personal information of customers of its Carnival, Holland America and Princess brands. It did not disclose how many may have been affected.</p>\n<p><b>Fox Corp.(FOXA) </b>– Fox increased its stock repurchase program by $2 billion to a total of $4 billion, helping to send its shares higher by 2.8% in the premarket.</p>\n<p><b>Pilgrim's Pride(PPC) </b>– Pilgrim's Pride expanded its prepared foods and branded products business by purchasing Kerry Group's Meats and Meals business. The poultry producer will pay the Ireland-based company about $947 million for that unit.</p>\n<p><b>Hasbro(HAS),Mattel(MAT) </b>– The toymakers are on watch following a New York Post report warning of a potential toy shortage this coming holiday season. The paper said thousands of toys ready for shipment remain stockpiled in China due to the lack of shipping containers available for export.</p>\n<p><b>Biogen(BIIB)</b> – The drugmaker's stock was upgraded to \"overweight\" from \"neutral\" at Piper Sandler, which cites a number of factors including the likelihood that doctors will prescribe Biogen's newly approved Alzheimer's drug Aduhelm. Biogen shares rose 1.7% in the premarket.</p>\n<p><b>Citigroup(C) </b>– The bank's stock remains on watch after declining for the past 11 consecutive trading days, losing 14% over that time.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147049745","content_text":"U.S. stock futures fell on Friday as the S&P 500 and the Dow Jones Industrial Average are on pace to post a losing week after the Federal Reserve's latest policy update.\nAt 8:05 a.m. ET, Dow E-minis were down 153 points, or 0.45%, S&P 500 E-minis were down 14.75 points, or 0.35% and Nasdaq 100 E-minis fell 18.5 points, or 0.13%.\n*Source From Tiger Trade, EST 08:05\nThe blue-chip Dow has lost 1.9% week to date, on pace for its worst week since January. The S&P 500 has fallen 0.6%. But the Nasdaq has gained 0.65% on the week.\nThe decline in stocks came amid a drastic flattening of the so-called Treasury yield curve where the yields of shorter-duration Treasurys, like the 2-year note, rose, while longer duration yields, such as the benchmark 10-year fell. The retreat in long-dated bonds reflects less optimism toward the economic growth, while the jump in short-end yields shows the expectations of the Fed raising rates.\nThe central bank's hawkish pivot on Wednesday caused volatile stock and bond market moves. Fed officials added two rate hikes to their 2023 forecast and increased their inflation projection for the year, while Fed Chairman Jerome Powell said officials have discussed tapering bond buying and would at some point begin slowing the asset purchases.\nFriday also coincides with the quarterly \"quadruple witching\" where options and futures on indexes and equities expire. Many expect trading to be more volatile in light of this event.\nStocks making the biggest moves in the premarket:\nAdobe(ADBE) – Adobe reported quarterly profit of $3.03 per share, 21 cents a share above estimates. The software company's revenue also topped Wall Street forecasts and Adobe gave stronger-than-expected current-quarter guidance. Its shares rose 3.1% in premarket trading.\nSmith & Wesson(SWBI) – Smith & Wesson reported better-than-expected profit and sales for its latest quarter, as the gun maker's sales surged 67% compared to the same quarter a year earlier. The company notes that its shipments jumped 70% compared to overall industry growth of 42%. Shares rallied 4.7% in premarket trading.\nOrphazyme(ORPH) – Orphazyme plunged 52.6% in the premarket after the Food and Drug Administration rejected its experimental treatment for a genetic disorder known as Niemann-Pick disease type C. The Denmark-based biotech company had seen volatile trading in its shares in recent days after it picked up social media attention, falling 10.2% Thursday after a more than 61% surge Wednesday.\nDelta Air Lines(DAL) – The stock added 1.1% in the premarket following a double upgrade at Wolfe Research to \"outperform\" from \"underperform.\" Wolfe said it sees business travel benefiting from pent-up demand later this summer, although it doesn't think it will return to pre-Covid levels.\nManchester United(MANU) – Manchester United lost $30.2 million for the first three months of this year, due largely to the absence of fans at its games because of the coronavirus pandemic. All of the team's 2020-21 season games were played without spectators.\nArcelorMittal(MT) – ArcelorMittal sold its remaining 38.2 million shares of steel producerCleveland-Cliffs(CLF). The mining company will use the proceeds to fund a $750 million share buyback. Arcelor-Mittal rose 1% in premarket action, while Cleveland-Cliffs added 0.3%.\nCarnival(CCL) – The cruise line operator disclosed a March data breach that may have exposed personal information of customers of its Carnival, Holland America and Princess brands. It did not disclose how many may have been affected.\nFox Corp.(FOXA) – Fox increased its stock repurchase program by $2 billion to a total of $4 billion, helping to send its shares higher by 2.8% in the premarket.\nPilgrim's Pride(PPC) – Pilgrim's Pride expanded its prepared foods and branded products business by purchasing Kerry Group's Meats and Meals business. The poultry producer will pay the Ireland-based company about $947 million for that unit.\nHasbro(HAS),Mattel(MAT) – The toymakers are on watch following a New York Post report warning of a potential toy shortage this coming holiday season. The paper said thousands of toys ready for shipment remain stockpiled in China due to the lack of shipping containers available for export.\nBiogen(BIIB) – The drugmaker's stock was upgraded to \"overweight\" from \"neutral\" at Piper Sandler, which cites a number of factors including the likelihood that doctors will prescribe Biogen's newly approved Alzheimer's drug Aduhelm. Biogen shares rose 1.7% in the premarket.\nCitigroup(C) – The bank's stock remains on watch after declining for the past 11 consecutive trading days, losing 14% over that time.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":392,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168915787,"gmtCreate":1623946605949,"gmtModify":1631889070690,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Team red!!","listText":"Team red!!","text":"Team red!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168915787","repostId":"2144374429","repostType":4,"isVote":1,"tweetType":1,"viewCount":240,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169438674,"gmtCreate":1623846707598,"gmtModify":1634027192711,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Sick. Need more dips","listText":"Sick. Need more dips","text":"Sick. Need more dips","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169438674","repostId":"1185341836","repostType":4,"repost":{"id":"1185341836","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623845207,"share":"https://www.laohu8.com/m/news/1185341836?lang=&edition=full","pubTime":"2021-06-16 20:06","market":"hk","language":"en","title":"Toplines Before US Market Open on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1185341836","media":"Tiger Newspress","summary":"U.S. stock index futures were mostly flat on Wednesday ahead of the Federal Reserve's update on mone","content":"<p>U.S. stock index futures were mostly flat on Wednesday ahead of the&nbsp;Federal Reserve's update&nbsp;on monetary policy.</p>\n<p>Futures contracts tied to the Dow Jones Industrial Average were just 46 points lower. S&amp;P 500 futures were largely flat, while Nasdaq 100 futures traded up by 0.1%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/33b560b1ab96b7a340369b24c17d6aa2\" tg-width=\"664\" tg-height=\"233\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:10</span></p>\n<p>The Fed has previously tried to assuage concerns that rising inflation would prompt it to tighten its ultra loose monetary policy, but data on Tuesday showing a jump in producer prices has again raised expectations the central bank could begin debating closing the taps at its meeting this week.</p>\n<p>The central bank's latest policy statement is expected to be released with fresh economic projections at 2 p.m. ET (1800 GMT).</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><b>Oracle(ORCL) </b>– Oracleearned $1.54 per sharefor its latest quarter, beating the consensus estimate of $1.31 a share. The business software company's revenue topped estimates as well. The company forecast current-quarter profit below consensus, however, as it increases investment in its cloud computing operations. Its shares fell 4.7% in premarket trading.</p>\n<p><b>Roblox(RBLX) </b>– Roblox tumbled 7.7% in the premarket after it reported 43 million daily active users for May, up 28% compared to a year earlier but down from 43.3 million in April. Spending by users of the videogame platform was down slightly from a year earlier.</p>\n<p><b>Kindred Biosciences(KIN)</b> – The pet therapeutics company agreed to be acquired byElanco Animal Health(ELAN) for $9.25 per share, or $440 million. Kindred had closed at $6.34 Tuesday, and its stock surged 44.6% in the premarket.</p>\n<p><b>La-Z-Boy(LZB) </b>– La-Z-Boy reported quarterly earnings of 87 cents per share, compared to a consensus estimate of 74 cents a share. The company best known for its reclining chairs also reported better-than-expected revenue. La-Z-Boy said it was being impacted by supply chain issues and significant increases in raw materials prices. Its shares lost 2.3% in the premarket.</p>\n<p><b>H&amp;R Block(HRB)</b> – H&amp;R Block beat Street forecasts for both profit and revenue in its latest quarter, and the tax preparation firm also raised its quarterly dividend by 4% to 27 cents per share. Additionally, H&amp;R Block is shifting the end of its fiscal year to June 30 from April 30, to better capture tax filing activity. H&amp;R Block shares slid 1.1% in premarket action.</p>\n<p><b>EBay(EBAY)</b> – The online marketplace operator will sell its South Korean unit to retailer Shinsegae's E-Mart unit and website operator Naver for about $3.6 billion, according to local media reports. E-Mart acknowledged the talks but said that no deal had been finalized.</p>\n<p><b>General Motors(GM) </b>– GM reportedly plans to boost global spending on electric and autonomous vehicles by 30% from its most recent forecast to a total of $35 billion through 2025. People briefed on the plans told Reuters that the spending will include two additional U.S. battery plants.</p>\n<p><b>Johnson &amp; Johnson(JNJ)</b> – The Food and Drug Administration cleared 15 million more doses of J&amp;J's Covid-19 vaccine that had been produced at a Baltimore plant run byEmergent Biosolutions(EBS). That brings the total of cleared doses to 25 million. Earlier, the FDA had rejected 60 million doses produced at that plant, saying Emergent hadn't taken proper precautions to prevent cross-contamination with another production line that was producingAstraZeneca's(AZN) Covid vaccine.</p>\n<p><b>Southwest Airlines(LUV) </b>– Southwest&nbsp;suffered its second computer glitch in 24 hoursTuesday, with a system outage leading to the cancellation of about 500 flights and delaying many others.</p>\n<p><b>Dish Network(DISH) </b>– The satellite TV company was upgraded to \"buy\" from \"hold\" at Pivotal Research, which cited the potential for Dish's 5G wireless network. Dish rose 1.7% in the premarket.</p>\n<p><b>Apollo Global(APO) </b>– Apollo sold textbook and educational technology company McGraw Hill to private-equity firm Platinum Equity for $4.5 billion.</p>\n<p><b>Regeneron(REGN) </b>– The drugmaker'sCovid-19 antibody cocktailreduced deaths in patients who could not mount their own antibody response, according to a newly published British study.</p>\n<p><b>SoFi Technologies(SOFI) </b>– The financial services platform was rated \"buy\" in new coverage at Rosenblatt Securities, noting SoFi's \"powerful\" cost advantage over legacy banks. SoFi shares rose 2.1% in the premarket.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-16 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stock index futures were mostly flat on Wednesday ahead of the&nbsp;Federal Reserve's update&nbsp;on monetary policy.</p>\n<p>Futures contracts tied to the Dow Jones Industrial Average were just 46 points lower. S&amp;P 500 futures were largely flat, while Nasdaq 100 futures traded up by 0.1%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/33b560b1ab96b7a340369b24c17d6aa2\" tg-width=\"664\" tg-height=\"233\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:10</span></p>\n<p>The Fed has previously tried to assuage concerns that rising inflation would prompt it to tighten its ultra loose monetary policy, but data on Tuesday showing a jump in producer prices has again raised expectations the central bank could begin debating closing the taps at its meeting this week.</p>\n<p>The central bank's latest policy statement is expected to be released with fresh economic projections at 2 p.m. ET (1800 GMT).</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><b>Oracle(ORCL) </b>– Oracleearned $1.54 per sharefor its latest quarter, beating the consensus estimate of $1.31 a share. The business software company's revenue topped estimates as well. The company forecast current-quarter profit below consensus, however, as it increases investment in its cloud computing operations. Its shares fell 4.7% in premarket trading.</p>\n<p><b>Roblox(RBLX) </b>– Roblox tumbled 7.7% in the premarket after it reported 43 million daily active users for May, up 28% compared to a year earlier but down from 43.3 million in April. Spending by users of the videogame platform was down slightly from a year earlier.</p>\n<p><b>Kindred Biosciences(KIN)</b> – The pet therapeutics company agreed to be acquired byElanco Animal Health(ELAN) for $9.25 per share, or $440 million. Kindred had closed at $6.34 Tuesday, and its stock surged 44.6% in the premarket.</p>\n<p><b>La-Z-Boy(LZB) </b>– La-Z-Boy reported quarterly earnings of 87 cents per share, compared to a consensus estimate of 74 cents a share. The company best known for its reclining chairs also reported better-than-expected revenue. La-Z-Boy said it was being impacted by supply chain issues and significant increases in raw materials prices. Its shares lost 2.3% in the premarket.</p>\n<p><b>H&amp;R Block(HRB)</b> – H&amp;R Block beat Street forecasts for both profit and revenue in its latest quarter, and the tax preparation firm also raised its quarterly dividend by 4% to 27 cents per share. Additionally, H&amp;R Block is shifting the end of its fiscal year to June 30 from April 30, to better capture tax filing activity. H&amp;R Block shares slid 1.1% in premarket action.</p>\n<p><b>EBay(EBAY)</b> – The online marketplace operator will sell its South Korean unit to retailer Shinsegae's E-Mart unit and website operator Naver for about $3.6 billion, according to local media reports. E-Mart acknowledged the talks but said that no deal had been finalized.</p>\n<p><b>General Motors(GM) </b>– GM reportedly plans to boost global spending on electric and autonomous vehicles by 30% from its most recent forecast to a total of $35 billion through 2025. People briefed on the plans told Reuters that the spending will include two additional U.S. battery plants.</p>\n<p><b>Johnson &amp; Johnson(JNJ)</b> – The Food and Drug Administration cleared 15 million more doses of J&amp;J's Covid-19 vaccine that had been produced at a Baltimore plant run byEmergent Biosolutions(EBS). That brings the total of cleared doses to 25 million. Earlier, the FDA had rejected 60 million doses produced at that plant, saying Emergent hadn't taken proper precautions to prevent cross-contamination with another production line that was producingAstraZeneca's(AZN) Covid vaccine.</p>\n<p><b>Southwest Airlines(LUV) </b>– Southwest&nbsp;suffered its second computer glitch in 24 hoursTuesday, with a system outage leading to the cancellation of about 500 flights and delaying many others.</p>\n<p><b>Dish Network(DISH) </b>– The satellite TV company was upgraded to \"buy\" from \"hold\" at Pivotal Research, which cited the potential for Dish's 5G wireless network. Dish rose 1.7% in the premarket.</p>\n<p><b>Apollo Global(APO) </b>– Apollo sold textbook and educational technology company McGraw Hill to private-equity firm Platinum Equity for $4.5 billion.</p>\n<p><b>Regeneron(REGN) </b>– The drugmaker'sCovid-19 antibody cocktailreduced deaths in patients who could not mount their own antibody response, according to a newly published British study.</p>\n<p><b>SoFi Technologies(SOFI) </b>– The financial services platform was rated \"buy\" in new coverage at Rosenblatt Securities, noting SoFi's \"powerful\" cost advantage over legacy banks. SoFi shares rose 2.1% in the premarket.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","ORCL":"甲骨文",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185341836","content_text":"U.S. stock index futures were mostly flat on Wednesday ahead of the Federal Reserve's update on monetary policy.\nFutures contracts tied to the Dow Jones Industrial Average were just 46 points lower. S&P 500 futures were largely flat, while Nasdaq 100 futures traded up by 0.1%.\n*Source From Tiger Trade, EST 08:10\nThe Fed has previously tried to assuage concerns that rising inflation would prompt it to tighten its ultra loose monetary policy, but data on Tuesday showing a jump in producer prices has again raised expectations the central bank could begin debating closing the taps at its meeting this week.\nThe central bank's latest policy statement is expected to be released with fresh economic projections at 2 p.m. ET (1800 GMT).\nStocks making the biggest moves in the premarket:\nOracle(ORCL) – Oracleearned $1.54 per sharefor its latest quarter, beating the consensus estimate of $1.31 a share. The business software company's revenue topped estimates as well. The company forecast current-quarter profit below consensus, however, as it increases investment in its cloud computing operations. Its shares fell 4.7% in premarket trading.\nRoblox(RBLX) – Roblox tumbled 7.7% in the premarket after it reported 43 million daily active users for May, up 28% compared to a year earlier but down from 43.3 million in April. Spending by users of the videogame platform was down slightly from a year earlier.\nKindred Biosciences(KIN) – The pet therapeutics company agreed to be acquired byElanco Animal Health(ELAN) for $9.25 per share, or $440 million. Kindred had closed at $6.34 Tuesday, and its stock surged 44.6% in the premarket.\nLa-Z-Boy(LZB) – La-Z-Boy reported quarterly earnings of 87 cents per share, compared to a consensus estimate of 74 cents a share. The company best known for its reclining chairs also reported better-than-expected revenue. La-Z-Boy said it was being impacted by supply chain issues and significant increases in raw materials prices. Its shares lost 2.3% in the premarket.\nH&R Block(HRB) – H&R Block beat Street forecasts for both profit and revenue in its latest quarter, and the tax preparation firm also raised its quarterly dividend by 4% to 27 cents per share. Additionally, H&R Block is shifting the end of its fiscal year to June 30 from April 30, to better capture tax filing activity. H&R Block shares slid 1.1% in premarket action.\nEBay(EBAY) – The online marketplace operator will sell its South Korean unit to retailer Shinsegae's E-Mart unit and website operator Naver for about $3.6 billion, according to local media reports. E-Mart acknowledged the talks but said that no deal had been finalized.\nGeneral Motors(GM) – GM reportedly plans to boost global spending on electric and autonomous vehicles by 30% from its most recent forecast to a total of $35 billion through 2025. People briefed on the plans told Reuters that the spending will include two additional U.S. battery plants.\nJohnson & Johnson(JNJ) – The Food and Drug Administration cleared 15 million more doses of J&J's Covid-19 vaccine that had been produced at a Baltimore plant run byEmergent Biosolutions(EBS). That brings the total of cleared doses to 25 million. Earlier, the FDA had rejected 60 million doses produced at that plant, saying Emergent hadn't taken proper precautions to prevent cross-contamination with another production line that was producingAstraZeneca's(AZN) Covid vaccine.\nSouthwest Airlines(LUV) – Southwest suffered its second computer glitch in 24 hoursTuesday, with a system outage leading to the cancellation of about 500 flights and delaying many others.\nDish Network(DISH) – The satellite TV company was upgraded to \"buy\" from \"hold\" at Pivotal Research, which cited the potential for Dish's 5G wireless network. Dish rose 1.7% in the premarket.\nApollo Global(APO) – Apollo sold textbook and educational technology company McGraw Hill to private-equity firm Platinum Equity for $4.5 billion.\nRegeneron(REGN) – The drugmaker'sCovid-19 antibody cocktailreduced deaths in patients who could not mount their own antibody response, according to a newly published British study.\nSoFi Technologies(SOFI) – The financial services platform was rated \"buy\" in new coverage at Rosenblatt Securities, noting SoFi's \"powerful\" cost advantage over legacy banks. SoFi shares rose 2.1% in the premarket.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"KIN":0.9,"ORCL":0.9}},"isVote":1,"tweetType":1,"viewCount":168,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169025031,"gmtCreate":1623809809123,"gmtModify":1634027774566,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169025031","repostId":"1144333499","repostType":4,"isVote":1,"tweetType":1,"viewCount":345,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187640213,"gmtCreate":1623753304332,"gmtModify":1634029017457,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187640213","repostId":"2143735244","repostType":4,"isVote":1,"tweetType":1,"viewCount":378,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187656548,"gmtCreate":1623753177184,"gmtModify":1634029021993,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Good to dip your toes into a little bit of crypto.&nbsp;","listText":"Good to dip your toes into a little bit of crypto.&nbsp;","text":"Good to dip your toes into a little bit of crypto.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187656548","repostId":"2143735752","repostType":4,"isVote":1,"tweetType":1,"viewCount":125,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":871185699,"gmtCreate":1637037132655,"gmtModify":1637037302349,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Pls drop so that i can buy more","listText":"Pls drop so that i can buy more","text":"Pls drop so that i can buy more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/871185699","repostId":"1160740007","repostType":4,"isVote":1,"tweetType":1,"viewCount":2023,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843581898,"gmtCreate":1635841643487,"gmtModify":1635841646978,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Go go go!!!&nbsp;","listText":"Go go go!!!&nbsp;","text":"Go go go!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/843581898","repostId":"1146954113","repostType":2,"repost":{"id":"1146954113","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635841327,"share":"https://www.laohu8.com/m/news/1146954113?lang=&edition=full","pubTime":"2021-11-02 16:22","market":"us","language":"en","title":"Novavax shares jumped another 4.4% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1146954113","media":"Tiger Newspress","summary":"Novavax shares jumped another 4.4% in premarket trading Tuesday after rising nearly 16% yesterday as","content":"<p>Novavax shares jumped another 4.4% in premarket trading&nbsp;Tuesday&nbsp;after rising nearly 16% yesterday&nbsp;as&nbsp;Novavax COVID-19 vaccine got first authorization; expected more within weeks.</p>\n<p><img src=\"https://static.tigerbbs.com/93777ff8ed669db1e3ea1516ae6b0f1f\" tg-width=\"849\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>Novavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within “weeks,” its chief executive told Reuters, after the shot on Monday received its first emergency use authorization (EUA) from Indonesia.</p>\n<p>The company also said it had filed an application for emergency use of the vaccine to Canada and the European Medicines Agency.</p>\n<p>For Indonesia, the shot will be manufactured by the world’s largest vaccine manufacturer, Serum Institute in India (SII), and sold under the Indian company’s brand name, Covovax. Novavax said initial shipments into Indonesia are expected to begin imminently.</p>\n<p>The World Health Organization (WHO) is also reviewing Novavax’s regulatory filing and the U.S. drugmaker expects that review to be resolved in the coming weeks, Chief Executive Stanley Erck told Reuters in a phone interview on Monday.</p>\n<p>A green light from the WHO would set the stage for Novavax to begin shipping doses to the COVAX program that supplies shots to low-income countries. Novavax and SII have together committed to provide more than 1.1 billion doses to COVAX, which is co-led by the WHO.</p>\n<p>“I think we’ll get some doses to COVAX this year,” Erck said. “But I think (Novavax is) going to really start being able to ship large quantity to COVAX in the first quarter” of 2022.</p>\n<p>Erck said Novavax has resolved all of its manufacturing challenges and does not expect regulators to have any further concerns about its production processes.</p>\n<p>He said Novavax is “in dialogue with the U.S. FDA and ... we expect a full submission within the next several weeks.”</p>\n<p>Novavax had delayed filing for U.S. approval, and Politico reported last month that the company faced production and quality problems.</p>\n<p>SII is authorized to make the Novavax vaccine and the U.S. company said it will apply for regulatory authorization for other facilities, such as its plant in the Czech republic, in the coming weeks.</p>\n<p>Indonesia is slated to receive 20 million doses of the protein-based vaccine this year, according to the government.</p>\n<p>Penny Lukito, chief of the National Agency for Drug and Food Control of Indonesia, did not immediately respond to a Reuters request for comment.</p>\n<p>Novavax has so far applied for EUA in various countries, including the UK, Australia, India and the Philippines.</p>\n<p>“It will be weeks, not months, for them to review” Novavax’s regulatory submissions and potentially clear the shot for use, Erck said.</p>\n<p>The company, along with Japanese partner Takeda Pharmaceutical Co, said on Friday it was preparing to seek regulatory approval for a rollout in Japan early next year.</p>\n<p>The Novavax shot was shown to be more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based trial.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax shares jumped another 4.4% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax shares jumped another 4.4% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-02 16:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novavax shares jumped another 4.4% in premarket trading&nbsp;Tuesday&nbsp;after rising nearly 16% yesterday&nbsp;as&nbsp;Novavax COVID-19 vaccine got first authorization; expected more within weeks.</p>\n<p><img src=\"https://static.tigerbbs.com/93777ff8ed669db1e3ea1516ae6b0f1f\" tg-width=\"849\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>Novavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within “weeks,” its chief executive told Reuters, after the shot on Monday received its first emergency use authorization (EUA) from Indonesia.</p>\n<p>The company also said it had filed an application for emergency use of the vaccine to Canada and the European Medicines Agency.</p>\n<p>For Indonesia, the shot will be manufactured by the world’s largest vaccine manufacturer, Serum Institute in India (SII), and sold under the Indian company’s brand name, Covovax. Novavax said initial shipments into Indonesia are expected to begin imminently.</p>\n<p>The World Health Organization (WHO) is also reviewing Novavax’s regulatory filing and the U.S. drugmaker expects that review to be resolved in the coming weeks, Chief Executive Stanley Erck told Reuters in a phone interview on Monday.</p>\n<p>A green light from the WHO would set the stage for Novavax to begin shipping doses to the COVAX program that supplies shots to low-income countries. Novavax and SII have together committed to provide more than 1.1 billion doses to COVAX, which is co-led by the WHO.</p>\n<p>“I think we’ll get some doses to COVAX this year,” Erck said. “But I think (Novavax is) going to really start being able to ship large quantity to COVAX in the first quarter” of 2022.</p>\n<p>Erck said Novavax has resolved all of its manufacturing challenges and does not expect regulators to have any further concerns about its production processes.</p>\n<p>He said Novavax is “in dialogue with the U.S. FDA and ... we expect a full submission within the next several weeks.”</p>\n<p>Novavax had delayed filing for U.S. approval, and Politico reported last month that the company faced production and quality problems.</p>\n<p>SII is authorized to make the Novavax vaccine and the U.S. company said it will apply for regulatory authorization for other facilities, such as its plant in the Czech republic, in the coming weeks.</p>\n<p>Indonesia is slated to receive 20 million doses of the protein-based vaccine this year, according to the government.</p>\n<p>Penny Lukito, chief of the National Agency for Drug and Food Control of Indonesia, did not immediately respond to a Reuters request for comment.</p>\n<p>Novavax has so far applied for EUA in various countries, including the UK, Australia, India and the Philippines.</p>\n<p>“It will be weeks, not months, for them to review” Novavax’s regulatory submissions and potentially clear the shot for use, Erck said.</p>\n<p>The company, along with Japanese partner Takeda Pharmaceutical Co, said on Friday it was preparing to seek regulatory approval for a rollout in Japan early next year.</p>\n<p>The Novavax shot was shown to be more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based trial.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146954113","content_text":"Novavax shares jumped another 4.4% in premarket trading Tuesday after rising nearly 16% yesterday as Novavax COVID-19 vaccine got first authorization; expected more within weeks.\n\nNovavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within “weeks,” its chief executive told Reuters, after the shot on Monday received its first emergency use authorization (EUA) from Indonesia.\nThe company also said it had filed an application for emergency use of the vaccine to Canada and the European Medicines Agency.\nFor Indonesia, the shot will be manufactured by the world’s largest vaccine manufacturer, Serum Institute in India (SII), and sold under the Indian company’s brand name, Covovax. Novavax said initial shipments into Indonesia are expected to begin imminently.\nThe World Health Organization (WHO) is also reviewing Novavax’s regulatory filing and the U.S. drugmaker expects that review to be resolved in the coming weeks, Chief Executive Stanley Erck told Reuters in a phone interview on Monday.\nA green light from the WHO would set the stage for Novavax to begin shipping doses to the COVAX program that supplies shots to low-income countries. Novavax and SII have together committed to provide more than 1.1 billion doses to COVAX, which is co-led by the WHO.\n“I think we’ll get some doses to COVAX this year,” Erck said. “But I think (Novavax is) going to really start being able to ship large quantity to COVAX in the first quarter” of 2022.\nErck said Novavax has resolved all of its manufacturing challenges and does not expect regulators to have any further concerns about its production processes.\nHe said Novavax is “in dialogue with the U.S. FDA and ... we expect a full submission within the next several weeks.”\nNovavax had delayed filing for U.S. approval, and Politico reported last month that the company faced production and quality problems.\nSII is authorized to make the Novavax vaccine and the U.S. company said it will apply for regulatory authorization for other facilities, such as its plant in the Czech republic, in the coming weeks.\nIndonesia is slated to receive 20 million doses of the protein-based vaccine this year, according to the government.\nPenny Lukito, chief of the National Agency for Drug and Food Control of Indonesia, did not immediately respond to a Reuters request for comment.\nNovavax has so far applied for EUA in various countries, including the UK, Australia, India and the Philippines.\n“It will be weeks, not months, for them to review” Novavax’s regulatory submissions and potentially clear the shot for use, Erck said.\nThe company, along with Japanese partner Takeda Pharmaceutical Co, said on Friday it was preparing to seek regulatory approval for a rollout in Japan early next year.\nThe Novavax shot was shown to be more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based trial.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1850,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841543109,"gmtCreate":1635928603322,"gmtModify":1635928603322,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"To the moon!!&nbsp;","listText":"To the moon!!&nbsp;","text":"To the moon!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/841543109","repostId":"1178338626","repostType":4,"repost":{"id":"1178338626","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635928227,"share":"https://www.laohu8.com/m/news/1178338626?lang=&edition=full","pubTime":"2021-11-03 16:30","market":"us","language":"en","title":"Some meme stocks skyrocketed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1178338626","media":"Tiger Newspress","summary":"Some meme stocks skyrocketed in premarket trading.Bed Bath & Beyond,R.R. Donnelley & Sons,Naked Bran","content":"<p>Some meme stocks skyrocketed in premarket trading.Bed Bath &amp; Beyond,R.R. Donnelley &amp; Sons,Naked Brand,Koss,Express,AMC,GameStop&nbsp;and&nbsp;BlackBerry&nbsp;soared between 4% and 62%.</p>\n<p><img src=\"https://static.tigerbbs.com/b016995062645d8011221cff13a86966\" tg-width=\"404\" tg-height=\"486\" referrerpolicy=\"no-referrer\"></p>\n<p><a href=\"https://laohu8.com/NW/1113177921\" target=\"_blank\">Bed Bath &amp; Beyond</a>,the home-goods retailer announced news that likely fueled a so-called short squeeze, where hedge funds that had bet against the stock were forced to buy back their shares to cut losses.</p>\n<p>Commercial-printing company&nbsp;R.R. Donnelley &amp; Sons&nbsp;Co.&nbsp;is nearing a deal to sell itself to a private-equity firm for just over $2 billion including debt, according to people familiar with the matter.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some meme stocks skyrocketed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome meme stocks skyrocketed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-03 16:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Some meme stocks skyrocketed in premarket trading.Bed Bath &amp; Beyond,R.R. Donnelley &amp; Sons,Naked Brand,Koss,Express,AMC,GameStop&nbsp;and&nbsp;BlackBerry&nbsp;soared between 4% and 62%.</p>\n<p><img src=\"https://static.tigerbbs.com/b016995062645d8011221cff13a86966\" tg-width=\"404\" tg-height=\"486\" referrerpolicy=\"no-referrer\"></p>\n<p><a href=\"https://laohu8.com/NW/1113177921\" target=\"_blank\">Bed Bath &amp; Beyond</a>,the home-goods retailer announced news that likely fueled a so-called short squeeze, where hedge funds that had bet against the stock were forced to buy back their shares to cut losses.</p>\n<p>Commercial-printing company&nbsp;R.R. Donnelley &amp; Sons&nbsp;Co.&nbsp;is nearing a deal to sell itself to a private-equity firm for just over $2 billion including debt, according to people familiar with the matter.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178338626","content_text":"Some meme stocks skyrocketed in premarket trading.Bed Bath & Beyond,R.R. Donnelley & Sons,Naked Brand,Koss,Express,AMC,GameStop and BlackBerry soared between 4% and 62%.\n\nBed Bath & Beyond,the home-goods retailer announced news that likely fueled a so-called short squeeze, where hedge funds that had bet against the stock were forced to buy back their shares to cut losses.\nCommercial-printing company R.R. Donnelley & Sons Co. is nearing a deal to sell itself to a private-equity firm for just over $2 billion including debt, according to people familiar with the matter.","news_type":1,"symbols_score_info":{"AMC":0.9,"BB":0.9,"BBBY":0.9,"EXPR":0.9,"GME":0.9,"KOSS":0.9,"NAKD":0.9,"RRD":0.9}},"isVote":1,"tweetType":1,"viewCount":1487,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859499264,"gmtCreate":1634718770094,"gmtModify":1634721067878,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Gg&nbsp;overpromise again","listText":"Gg&nbsp;overpromise again","text":"Gg overpromise again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859499264","repostId":"1174375951","repostType":2,"repost":{"id":"1174375951","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634717661,"share":"https://www.laohu8.com/m/news/1174375951?lang=&edition=full","pubTime":"2021-10-20 16:14","market":"us","language":"en","title":"Novavax plunged over 20% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1174375951","media":"Tiger Newspress","summary":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the pr","content":"<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p>\n<p><img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p>\n<p>But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p>\n<p>The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p>\n<p>The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p>\n<p>Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p>\n<p>The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p>\n<p>COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p>\n<p>“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p>\n<p>The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p>\n<p>Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p>\n<p>In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p>\n<p>“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p>\n<p>The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p>\n<p>But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p>\n<p>Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p>\n<p>Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p>\n<p>The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p>\n<p>That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p>\n<p>Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p>\n<p>J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p>\n<p>“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p>\n<p>Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p>\n<p>Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p>\n<p>The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p>\n<p>But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p>\n<p>In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p>\n<p>“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p>\n<p>Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p>\n<p>Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p>\n<p>“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p>\n<p>U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p>\n<p>And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p>\n<p>Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p>\n<p>“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax plunged over 20% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax plunged over 20% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-20 16:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p>\n<p><img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p>\n<p>But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p>\n<p>The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p>\n<p>The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p>\n<p>Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p>\n<p>The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p>\n<p>COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p>\n<p>“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p>\n<p>The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p>\n<p>Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p>\n<p>In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p>\n<p>“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p>\n<p>The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p>\n<p>But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p>\n<p>Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p>\n<p>Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p>\n<p>The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p>\n<p>That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p>\n<p>Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p>\n<p>J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p>\n<p>“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p>\n<p>Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p>\n<p>Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p>\n<p>The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p>\n<p>But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p>\n<p>In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p>\n<p>“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p>\n<p>Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p>\n<p>Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p>\n<p>“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p>\n<p>U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p>\n<p>And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p>\n<p>Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p>\n<p>“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174375951","content_text":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.\nThe world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.\nBut the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.\nThe delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.\nThe U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.\nAlthough Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.\nThe Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, one of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.\nCOVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.\n“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the Duke Global Health Innovation Center.\nThe global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.\nBetween Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.\nIn a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.\n“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.\nThe White House and the Department of Health and Human Services did not respond to multiple requests for comment.\nBut three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.\nNovavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.\nUnlike Pfizer and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.\nThe revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.\nThat includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.\nNovavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson & Johnsonhalted work at a Baltimore facilityrun by contract manufacturer Emergent BioSolutions after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.\nJ&J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.\n“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”\nUnlike Johnson & Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.\nYet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.\nThe contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.\nBut even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.\nIn particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.\n“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”\nTaylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.\nCompany executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.\n“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”\nU.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&J’s vaccine at the Emergent plant earlier this year, those people said.\nAnd even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.\nSeveral vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.\n“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1506,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603619690,"gmtCreate":1638404643257,"gmtModify":1638404643467,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Not the time yet","listText":"Not the time yet","text":"Not the time yet","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603619690","repostId":"2188690505","repostType":4,"isVote":1,"tweetType":1,"viewCount":2741,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850281587,"gmtCreate":1634602242348,"gmtModify":1634602242420,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Very good","listText":"Very good","text":"Very good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850281587","repostId":"1114416896","repostType":4,"isVote":1,"tweetType":1,"viewCount":1488,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829404697,"gmtCreate":1633530962458,"gmtModify":1633530962530,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"why sell???","listText":"why sell???","text":"why sell???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829404697","repostId":"1126696993","repostType":2,"isVote":1,"tweetType":1,"viewCount":1775,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606853487,"gmtCreate":1638861086065,"gmtModify":1638861086179,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"EV to the moon","listText":"EV to the moon","text":"EV to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606853487","repostId":"2189682681","repostType":4,"isVote":1,"tweetType":1,"viewCount":2480,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":851838102,"gmtCreate":1634890474595,"gmtModify":1634890474595,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMD\">$AMD(AMD)$</a>&nbsp;up up up!!!&nbsp;","listText":"<a href=\"https://laohu8.com/S/AMD\">$AMD(AMD)$</a>&nbsp;up up up!!!&nbsp;","text":"$AMD(AMD)$ up up up!!!","images":[{"img":"https://static.tigerbbs.com/2da1478496dda3d23161f71934bb6c2b","width":"1080","height":"2375"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/851838102","isVote":1,"tweetType":1,"viewCount":1724,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":839362705,"gmtCreate":1629122847907,"gmtModify":1633687233567,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"loving the reds","listText":"loving the reds","text":"loving the reds","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/839362705","repostId":"1133200546","repostType":4,"isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166466282,"gmtCreate":1624023123946,"gmtModify":1634023985172,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166466282","repostId":"1147049745","repostType":4,"repost":{"id":"1147049745","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624018214,"share":"https://www.laohu8.com/m/news/1147049745?lang=&edition=full","pubTime":"2021-06-18 20:10","market":"us","language":"en","title":"Toplines Before US Market Open on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1147049745","media":"Tiger Newspress","summary":"U.S. stock futures fell on Friday as the S&P 500 and the Dow Jones Industrial Average are on pace to","content":"<p>U.S. stock futures fell on Friday as the S&amp;P 500 and the Dow Jones Industrial Average are on pace to post a losing week after the Federal Reserve's latest policy update.</p>\n<p>At 8:05 a.m. ET, Dow E-minis were down 153 points, or 0.45%, S&amp;P 500 E-minis were down 14.75 points, or 0.35% and Nasdaq 100 E-minis fell 18.5 points, or 0.13%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/25234fe10c0fe8a9e73f2cec66447216\" tg-width=\"1003\" tg-height=\"316\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:05</span></p>\n<p>The blue-chip Dow has lost 1.9% week to date, on pace for its worst week since January. The S&amp;P 500 has fallen 0.6%. But the Nasdaq has gained 0.65% on the week.</p>\n<p>The decline in stocks came amid a drastic flattening of the so-called Treasury yield curve&nbsp;where the yields of shorter-duration Treasurys, like the&nbsp;2-year note, rose, while longer duration yields, such as the benchmark 10-year fell.&nbsp;The retreat in long-dated bonds reflects less optimism toward the economic growth, while the jump in short-end yields shows the expectations of the Fed raising rates.</p>\n<p>The central bank's hawkish pivot on Wednesday&nbsp;caused volatile stock and bond market moves. Fed officials added two rate hikes to their 2023 forecast and increased their inflation projection for the year, while Fed Chairman Jerome Powell said officials have discussed tapering bond buying and would at some point begin slowing the asset purchases.</p>\n<p>Friday also coincides with the quarterly \"quadruple witching\" where options and futures on indexes and equities expire. Many expect trading to be more volatile in light of this event.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><b>Adobe(ADBE) </b>– Adobe reported quarterly profit of $3.03 per share, 21 cents a share above estimates. The software company's revenue also topped Wall Street forecasts and Adobe gave stronger-than-expected current-quarter guidance. Its shares rose 3.1% in premarket trading.</p>\n<p><b>Smith &amp; Wesson(SWBI) </b>– Smith &amp; Wesson reported better-than-expected profit and sales for its latest quarter, as the gun maker's sales surged 67% compared to the same quarter a year earlier. The company notes that its shipments jumped 70% compared to overall industry growth of 42%. Shares rallied 4.7% in premarket trading.</p>\n<p><b>Orphazyme(ORPH)</b> – Orphazyme plunged 52.6% in the premarket after the Food and Drug Administration rejected its experimental treatment for a genetic disorder known as Niemann-Pick disease type C. The Denmark-based biotech company had seen volatile trading in its shares in recent days after it picked up social media attention, falling 10.2% Thursday after a more than 61% surge Wednesday.</p>\n<p><b>Delta Air Lines(DAL)</b> – The stock added 1.1% in the premarket following a double upgrade at Wolfe Research to \"outperform\" from \"underperform.\" Wolfe said it sees business travel benefiting from pent-up demand later this summer, although it doesn't think it will return to pre-Covid levels.</p>\n<p><b>Manchester United(MANU) </b>– Manchester United lost $30.2 million for the first three months of this year, due largely to the absence of fans at its games because of the coronavirus pandemic. All of the team's 2020-21 season games were played without spectators.</p>\n<p><b>ArcelorMittal(MT) </b>– ArcelorMittal sold its remaining 38.2 million shares of steel producerCleveland-Cliffs(CLF). The mining company will use the proceeds to fund a $750 million share buyback. Arcelor-Mittal rose 1% in premarket action, while Cleveland-Cliffs added 0.3%.</p>\n<p><b>Carnival(CCL) </b>– The cruise line operator disclosed a March data breach that may have exposed personal information of customers of its Carnival, Holland America and Princess brands. It did not disclose how many may have been affected.</p>\n<p><b>Fox Corp.(FOXA) </b>– Fox increased its stock repurchase program by $2 billion to a total of $4 billion, helping to send its shares higher by 2.8% in the premarket.</p>\n<p><b>Pilgrim's Pride(PPC) </b>– Pilgrim's Pride expanded its prepared foods and branded products business by purchasing Kerry Group's Meats and Meals business. The poultry producer will pay the Ireland-based company about $947 million for that unit.</p>\n<p><b>Hasbro(HAS),Mattel(MAT) </b>– The toymakers are on watch following a New York Post report warning of a potential toy shortage this coming holiday season. The paper said thousands of toys ready for shipment remain stockpiled in China due to the lack of shipping containers available for export.</p>\n<p><b>Biogen(BIIB)</b> – The drugmaker's stock was upgraded to \"overweight\" from \"neutral\" at Piper Sandler, which cites a number of factors including the likelihood that doctors will prescribe Biogen's newly approved Alzheimer's drug Aduhelm. Biogen shares rose 1.7% in the premarket.</p>\n<p><b>Citigroup(C) </b>– The bank's stock remains on watch after declining for the past 11 consecutive trading days, losing 14% over that time.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-18 20:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stock futures fell on Friday as the S&amp;P 500 and the Dow Jones Industrial Average are on pace to post a losing week after the Federal Reserve's latest policy update.</p>\n<p>At 8:05 a.m. ET, Dow E-minis were down 153 points, or 0.45%, S&amp;P 500 E-minis were down 14.75 points, or 0.35% and Nasdaq 100 E-minis fell 18.5 points, or 0.13%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/25234fe10c0fe8a9e73f2cec66447216\" tg-width=\"1003\" tg-height=\"316\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:05</span></p>\n<p>The blue-chip Dow has lost 1.9% week to date, on pace for its worst week since January. The S&amp;P 500 has fallen 0.6%. But the Nasdaq has gained 0.65% on the week.</p>\n<p>The decline in stocks came amid a drastic flattening of the so-called Treasury yield curve&nbsp;where the yields of shorter-duration Treasurys, like the&nbsp;2-year note, rose, while longer duration yields, such as the benchmark 10-year fell.&nbsp;The retreat in long-dated bonds reflects less optimism toward the economic growth, while the jump in short-end yields shows the expectations of the Fed raising rates.</p>\n<p>The central bank's hawkish pivot on Wednesday&nbsp;caused volatile stock and bond market moves. Fed officials added two rate hikes to their 2023 forecast and increased their inflation projection for the year, while Fed Chairman Jerome Powell said officials have discussed tapering bond buying and would at some point begin slowing the asset purchases.</p>\n<p>Friday also coincides with the quarterly \"quadruple witching\" where options and futures on indexes and equities expire. Many expect trading to be more volatile in light of this event.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><b>Adobe(ADBE) </b>– Adobe reported quarterly profit of $3.03 per share, 21 cents a share above estimates. The software company's revenue also topped Wall Street forecasts and Adobe gave stronger-than-expected current-quarter guidance. Its shares rose 3.1% in premarket trading.</p>\n<p><b>Smith &amp; Wesson(SWBI) </b>– Smith &amp; Wesson reported better-than-expected profit and sales for its latest quarter, as the gun maker's sales surged 67% compared to the same quarter a year earlier. The company notes that its shipments jumped 70% compared to overall industry growth of 42%. Shares rallied 4.7% in premarket trading.</p>\n<p><b>Orphazyme(ORPH)</b> – Orphazyme plunged 52.6% in the premarket after the Food and Drug Administration rejected its experimental treatment for a genetic disorder known as Niemann-Pick disease type C. The Denmark-based biotech company had seen volatile trading in its shares in recent days after it picked up social media attention, falling 10.2% Thursday after a more than 61% surge Wednesday.</p>\n<p><b>Delta Air Lines(DAL)</b> – The stock added 1.1% in the premarket following a double upgrade at Wolfe Research to \"outperform\" from \"underperform.\" Wolfe said it sees business travel benefiting from pent-up demand later this summer, although it doesn't think it will return to pre-Covid levels.</p>\n<p><b>Manchester United(MANU) </b>– Manchester United lost $30.2 million for the first three months of this year, due largely to the absence of fans at its games because of the coronavirus pandemic. All of the team's 2020-21 season games were played without spectators.</p>\n<p><b>ArcelorMittal(MT) </b>– ArcelorMittal sold its remaining 38.2 million shares of steel producerCleveland-Cliffs(CLF). The mining company will use the proceeds to fund a $750 million share buyback. Arcelor-Mittal rose 1% in premarket action, while Cleveland-Cliffs added 0.3%.</p>\n<p><b>Carnival(CCL) </b>– The cruise line operator disclosed a March data breach that may have exposed personal information of customers of its Carnival, Holland America and Princess brands. It did not disclose how many may have been affected.</p>\n<p><b>Fox Corp.(FOXA) </b>– Fox increased its stock repurchase program by $2 billion to a total of $4 billion, helping to send its shares higher by 2.8% in the premarket.</p>\n<p><b>Pilgrim's Pride(PPC) </b>– Pilgrim's Pride expanded its prepared foods and branded products business by purchasing Kerry Group's Meats and Meals business. The poultry producer will pay the Ireland-based company about $947 million for that unit.</p>\n<p><b>Hasbro(HAS),Mattel(MAT) </b>– The toymakers are on watch following a New York Post report warning of a potential toy shortage this coming holiday season. The paper said thousands of toys ready for shipment remain stockpiled in China due to the lack of shipping containers available for export.</p>\n<p><b>Biogen(BIIB)</b> – The drugmaker's stock was upgraded to \"overweight\" from \"neutral\" at Piper Sandler, which cites a number of factors including the likelihood that doctors will prescribe Biogen's newly approved Alzheimer's drug Aduhelm. Biogen shares rose 1.7% in the premarket.</p>\n<p><b>Citigroup(C) </b>– The bank's stock remains on watch after declining for the past 11 consecutive trading days, losing 14% over that time.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147049745","content_text":"U.S. stock futures fell on Friday as the S&P 500 and the Dow Jones Industrial Average are on pace to post a losing week after the Federal Reserve's latest policy update.\nAt 8:05 a.m. ET, Dow E-minis were down 153 points, or 0.45%, S&P 500 E-minis were down 14.75 points, or 0.35% and Nasdaq 100 E-minis fell 18.5 points, or 0.13%.\n*Source From Tiger Trade, EST 08:05\nThe blue-chip Dow has lost 1.9% week to date, on pace for its worst week since January. The S&P 500 has fallen 0.6%. But the Nasdaq has gained 0.65% on the week.\nThe decline in stocks came amid a drastic flattening of the so-called Treasury yield curve where the yields of shorter-duration Treasurys, like the 2-year note, rose, while longer duration yields, such as the benchmark 10-year fell. The retreat in long-dated bonds reflects less optimism toward the economic growth, while the jump in short-end yields shows the expectations of the Fed raising rates.\nThe central bank's hawkish pivot on Wednesday caused volatile stock and bond market moves. Fed officials added two rate hikes to their 2023 forecast and increased their inflation projection for the year, while Fed Chairman Jerome Powell said officials have discussed tapering bond buying and would at some point begin slowing the asset purchases.\nFriday also coincides with the quarterly \"quadruple witching\" where options and futures on indexes and equities expire. Many expect trading to be more volatile in light of this event.\nStocks making the biggest moves in the premarket:\nAdobe(ADBE) – Adobe reported quarterly profit of $3.03 per share, 21 cents a share above estimates. The software company's revenue also topped Wall Street forecasts and Adobe gave stronger-than-expected current-quarter guidance. Its shares rose 3.1% in premarket trading.\nSmith & Wesson(SWBI) – Smith & Wesson reported better-than-expected profit and sales for its latest quarter, as the gun maker's sales surged 67% compared to the same quarter a year earlier. The company notes that its shipments jumped 70% compared to overall industry growth of 42%. Shares rallied 4.7% in premarket trading.\nOrphazyme(ORPH) – Orphazyme plunged 52.6% in the premarket after the Food and Drug Administration rejected its experimental treatment for a genetic disorder known as Niemann-Pick disease type C. The Denmark-based biotech company had seen volatile trading in its shares in recent days after it picked up social media attention, falling 10.2% Thursday after a more than 61% surge Wednesday.\nDelta Air Lines(DAL) – The stock added 1.1% in the premarket following a double upgrade at Wolfe Research to \"outperform\" from \"underperform.\" Wolfe said it sees business travel benefiting from pent-up demand later this summer, although it doesn't think it will return to pre-Covid levels.\nManchester United(MANU) – Manchester United lost $30.2 million for the first three months of this year, due largely to the absence of fans at its games because of the coronavirus pandemic. All of the team's 2020-21 season games were played without spectators.\nArcelorMittal(MT) – ArcelorMittal sold its remaining 38.2 million shares of steel producerCleveland-Cliffs(CLF). The mining company will use the proceeds to fund a $750 million share buyback. Arcelor-Mittal rose 1% in premarket action, while Cleveland-Cliffs added 0.3%.\nCarnival(CCL) – The cruise line operator disclosed a March data breach that may have exposed personal information of customers of its Carnival, Holland America and Princess brands. It did not disclose how many may have been affected.\nFox Corp.(FOXA) – Fox increased its stock repurchase program by $2 billion to a total of $4 billion, helping to send its shares higher by 2.8% in the premarket.\nPilgrim's Pride(PPC) – Pilgrim's Pride expanded its prepared foods and branded products business by purchasing Kerry Group's Meats and Meals business. The poultry producer will pay the Ireland-based company about $947 million for that unit.\nHasbro(HAS),Mattel(MAT) – The toymakers are on watch following a New York Post report warning of a potential toy shortage this coming holiday season. The paper said thousands of toys ready for shipment remain stockpiled in China due to the lack of shipping containers available for export.\nBiogen(BIIB) – The drugmaker's stock was upgraded to \"overweight\" from \"neutral\" at Piper Sandler, which cites a number of factors including the likelihood that doctors will prescribe Biogen's newly approved Alzheimer's drug Aduhelm. Biogen shares rose 1.7% in the premarket.\nCitigroup(C) – The bank's stock remains on watch after declining for the past 11 consecutive trading days, losing 14% over that time.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":392,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169025031,"gmtCreate":1623809809123,"gmtModify":1634027774566,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169025031","repostId":"1144333499","repostType":4,"isVote":1,"tweetType":1,"viewCount":345,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":829410404,"gmtCreate":1633532533184,"gmtModify":1633532533259,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"But why stock price still drop??&nbsp;","listText":"But why stock price still drop??&nbsp;","text":"But why stock price still drop??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829410404","repostId":"1169679917","repostType":2,"isVote":1,"tweetType":1,"viewCount":1501,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":168915787,"gmtCreate":1623946605949,"gmtModify":1631889070690,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Team red!!","listText":"Team red!!","text":"Team red!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168915787","repostId":"2144374429","repostType":4,"isVote":1,"tweetType":1,"viewCount":240,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169438674,"gmtCreate":1623846707598,"gmtModify":1634027192711,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Sick. Need more dips","listText":"Sick. Need more dips","text":"Sick. Need more dips","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169438674","repostId":"1185341836","repostType":4,"repost":{"id":"1185341836","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623845207,"share":"https://www.laohu8.com/m/news/1185341836?lang=&edition=full","pubTime":"2021-06-16 20:06","market":"hk","language":"en","title":"Toplines Before US Market Open on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1185341836","media":"Tiger Newspress","summary":"U.S. stock index futures were mostly flat on Wednesday ahead of the Federal Reserve's update on mone","content":"<p>U.S. stock index futures were mostly flat on Wednesday ahead of the&nbsp;Federal Reserve's update&nbsp;on monetary policy.</p>\n<p>Futures contracts tied to the Dow Jones Industrial Average were just 46 points lower. S&amp;P 500 futures were largely flat, while Nasdaq 100 futures traded up by 0.1%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/33b560b1ab96b7a340369b24c17d6aa2\" tg-width=\"664\" tg-height=\"233\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:10</span></p>\n<p>The Fed has previously tried to assuage concerns that rising inflation would prompt it to tighten its ultra loose monetary policy, but data on Tuesday showing a jump in producer prices has again raised expectations the central bank could begin debating closing the taps at its meeting this week.</p>\n<p>The central bank's latest policy statement is expected to be released with fresh economic projections at 2 p.m. ET (1800 GMT).</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><b>Oracle(ORCL) </b>– Oracleearned $1.54 per sharefor its latest quarter, beating the consensus estimate of $1.31 a share. The business software company's revenue topped estimates as well. The company forecast current-quarter profit below consensus, however, as it increases investment in its cloud computing operations. Its shares fell 4.7% in premarket trading.</p>\n<p><b>Roblox(RBLX) </b>– Roblox tumbled 7.7% in the premarket after it reported 43 million daily active users for May, up 28% compared to a year earlier but down from 43.3 million in April. Spending by users of the videogame platform was down slightly from a year earlier.</p>\n<p><b>Kindred Biosciences(KIN)</b> – The pet therapeutics company agreed to be acquired byElanco Animal Health(ELAN) for $9.25 per share, or $440 million. Kindred had closed at $6.34 Tuesday, and its stock surged 44.6% in the premarket.</p>\n<p><b>La-Z-Boy(LZB) </b>– La-Z-Boy reported quarterly earnings of 87 cents per share, compared to a consensus estimate of 74 cents a share. The company best known for its reclining chairs also reported better-than-expected revenue. La-Z-Boy said it was being impacted by supply chain issues and significant increases in raw materials prices. Its shares lost 2.3% in the premarket.</p>\n<p><b>H&amp;R Block(HRB)</b> – H&amp;R Block beat Street forecasts for both profit and revenue in its latest quarter, and the tax preparation firm also raised its quarterly dividend by 4% to 27 cents per share. Additionally, H&amp;R Block is shifting the end of its fiscal year to June 30 from April 30, to better capture tax filing activity. H&amp;R Block shares slid 1.1% in premarket action.</p>\n<p><b>EBay(EBAY)</b> – The online marketplace operator will sell its South Korean unit to retailer Shinsegae's E-Mart unit and website operator Naver for about $3.6 billion, according to local media reports. E-Mart acknowledged the talks but said that no deal had been finalized.</p>\n<p><b>General Motors(GM) </b>– GM reportedly plans to boost global spending on electric and autonomous vehicles by 30% from its most recent forecast to a total of $35 billion through 2025. People briefed on the plans told Reuters that the spending will include two additional U.S. battery plants.</p>\n<p><b>Johnson &amp; Johnson(JNJ)</b> – The Food and Drug Administration cleared 15 million more doses of J&amp;J's Covid-19 vaccine that had been produced at a Baltimore plant run byEmergent Biosolutions(EBS). That brings the total of cleared doses to 25 million. Earlier, the FDA had rejected 60 million doses produced at that plant, saying Emergent hadn't taken proper precautions to prevent cross-contamination with another production line that was producingAstraZeneca's(AZN) Covid vaccine.</p>\n<p><b>Southwest Airlines(LUV) </b>– Southwest&nbsp;suffered its second computer glitch in 24 hoursTuesday, with a system outage leading to the cancellation of about 500 flights and delaying many others.</p>\n<p><b>Dish Network(DISH) </b>– The satellite TV company was upgraded to \"buy\" from \"hold\" at Pivotal Research, which cited the potential for Dish's 5G wireless network. Dish rose 1.7% in the premarket.</p>\n<p><b>Apollo Global(APO) </b>– Apollo sold textbook and educational technology company McGraw Hill to private-equity firm Platinum Equity for $4.5 billion.</p>\n<p><b>Regeneron(REGN) </b>– The drugmaker'sCovid-19 antibody cocktailreduced deaths in patients who could not mount their own antibody response, according to a newly published British study.</p>\n<p><b>SoFi Technologies(SOFI) </b>– The financial services platform was rated \"buy\" in new coverage at Rosenblatt Securities, noting SoFi's \"powerful\" cost advantage over legacy banks. SoFi shares rose 2.1% in the premarket.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-16 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stock index futures were mostly flat on Wednesday ahead of the&nbsp;Federal Reserve's update&nbsp;on monetary policy.</p>\n<p>Futures contracts tied to the Dow Jones Industrial Average were just 46 points lower. S&amp;P 500 futures were largely flat, while Nasdaq 100 futures traded up by 0.1%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/33b560b1ab96b7a340369b24c17d6aa2\" tg-width=\"664\" tg-height=\"233\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:10</span></p>\n<p>The Fed has previously tried to assuage concerns that rising inflation would prompt it to tighten its ultra loose monetary policy, but data on Tuesday showing a jump in producer prices has again raised expectations the central bank could begin debating closing the taps at its meeting this week.</p>\n<p>The central bank's latest policy statement is expected to be released with fresh economic projections at 2 p.m. ET (1800 GMT).</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><b>Oracle(ORCL) </b>– Oracleearned $1.54 per sharefor its latest quarter, beating the consensus estimate of $1.31 a share. The business software company's revenue topped estimates as well. The company forecast current-quarter profit below consensus, however, as it increases investment in its cloud computing operations. Its shares fell 4.7% in premarket trading.</p>\n<p><b>Roblox(RBLX) </b>– Roblox tumbled 7.7% in the premarket after it reported 43 million daily active users for May, up 28% compared to a year earlier but down from 43.3 million in April. Spending by users of the videogame platform was down slightly from a year earlier.</p>\n<p><b>Kindred Biosciences(KIN)</b> – The pet therapeutics company agreed to be acquired byElanco Animal Health(ELAN) for $9.25 per share, or $440 million. Kindred had closed at $6.34 Tuesday, and its stock surged 44.6% in the premarket.</p>\n<p><b>La-Z-Boy(LZB) </b>– La-Z-Boy reported quarterly earnings of 87 cents per share, compared to a consensus estimate of 74 cents a share. The company best known for its reclining chairs also reported better-than-expected revenue. La-Z-Boy said it was being impacted by supply chain issues and significant increases in raw materials prices. Its shares lost 2.3% in the premarket.</p>\n<p><b>H&amp;R Block(HRB)</b> – H&amp;R Block beat Street forecasts for both profit and revenue in its latest quarter, and the tax preparation firm also raised its quarterly dividend by 4% to 27 cents per share. Additionally, H&amp;R Block is shifting the end of its fiscal year to June 30 from April 30, to better capture tax filing activity. H&amp;R Block shares slid 1.1% in premarket action.</p>\n<p><b>EBay(EBAY)</b> – The online marketplace operator will sell its South Korean unit to retailer Shinsegae's E-Mart unit and website operator Naver for about $3.6 billion, according to local media reports. E-Mart acknowledged the talks but said that no deal had been finalized.</p>\n<p><b>General Motors(GM) </b>– GM reportedly plans to boost global spending on electric and autonomous vehicles by 30% from its most recent forecast to a total of $35 billion through 2025. People briefed on the plans told Reuters that the spending will include two additional U.S. battery plants.</p>\n<p><b>Johnson &amp; Johnson(JNJ)</b> – The Food and Drug Administration cleared 15 million more doses of J&amp;J's Covid-19 vaccine that had been produced at a Baltimore plant run byEmergent Biosolutions(EBS). That brings the total of cleared doses to 25 million. Earlier, the FDA had rejected 60 million doses produced at that plant, saying Emergent hadn't taken proper precautions to prevent cross-contamination with another production line that was producingAstraZeneca's(AZN) Covid vaccine.</p>\n<p><b>Southwest Airlines(LUV) </b>– Southwest&nbsp;suffered its second computer glitch in 24 hoursTuesday, with a system outage leading to the cancellation of about 500 flights and delaying many others.</p>\n<p><b>Dish Network(DISH) </b>– The satellite TV company was upgraded to \"buy\" from \"hold\" at Pivotal Research, which cited the potential for Dish's 5G wireless network. Dish rose 1.7% in the premarket.</p>\n<p><b>Apollo Global(APO) </b>– Apollo sold textbook and educational technology company McGraw Hill to private-equity firm Platinum Equity for $4.5 billion.</p>\n<p><b>Regeneron(REGN) </b>– The drugmaker'sCovid-19 antibody cocktailreduced deaths in patients who could not mount their own antibody response, according to a newly published British study.</p>\n<p><b>SoFi Technologies(SOFI) </b>– The financial services platform was rated \"buy\" in new coverage at Rosenblatt Securities, noting SoFi's \"powerful\" cost advantage over legacy banks. SoFi shares rose 2.1% in the premarket.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","ORCL":"甲骨文",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185341836","content_text":"U.S. stock index futures were mostly flat on Wednesday ahead of the Federal Reserve's update on monetary policy.\nFutures contracts tied to the Dow Jones Industrial Average were just 46 points lower. S&P 500 futures were largely flat, while Nasdaq 100 futures traded up by 0.1%.\n*Source From Tiger Trade, EST 08:10\nThe Fed has previously tried to assuage concerns that rising inflation would prompt it to tighten its ultra loose monetary policy, but data on Tuesday showing a jump in producer prices has again raised expectations the central bank could begin debating closing the taps at its meeting this week.\nThe central bank's latest policy statement is expected to be released with fresh economic projections at 2 p.m. ET (1800 GMT).\nStocks making the biggest moves in the premarket:\nOracle(ORCL) – Oracleearned $1.54 per sharefor its latest quarter, beating the consensus estimate of $1.31 a share. The business software company's revenue topped estimates as well. The company forecast current-quarter profit below consensus, however, as it increases investment in its cloud computing operations. Its shares fell 4.7% in premarket trading.\nRoblox(RBLX) – Roblox tumbled 7.7% in the premarket after it reported 43 million daily active users for May, up 28% compared to a year earlier but down from 43.3 million in April. Spending by users of the videogame platform was down slightly from a year earlier.\nKindred Biosciences(KIN) – The pet therapeutics company agreed to be acquired byElanco Animal Health(ELAN) for $9.25 per share, or $440 million. Kindred had closed at $6.34 Tuesday, and its stock surged 44.6% in the premarket.\nLa-Z-Boy(LZB) – La-Z-Boy reported quarterly earnings of 87 cents per share, compared to a consensus estimate of 74 cents a share. The company best known for its reclining chairs also reported better-than-expected revenue. La-Z-Boy said it was being impacted by supply chain issues and significant increases in raw materials prices. Its shares lost 2.3% in the premarket.\nH&R Block(HRB) – H&R Block beat Street forecasts for both profit and revenue in its latest quarter, and the tax preparation firm also raised its quarterly dividend by 4% to 27 cents per share. Additionally, H&R Block is shifting the end of its fiscal year to June 30 from April 30, to better capture tax filing activity. H&R Block shares slid 1.1% in premarket action.\nEBay(EBAY) – The online marketplace operator will sell its South Korean unit to retailer Shinsegae's E-Mart unit and website operator Naver for about $3.6 billion, according to local media reports. E-Mart acknowledged the talks but said that no deal had been finalized.\nGeneral Motors(GM) – GM reportedly plans to boost global spending on electric and autonomous vehicles by 30% from its most recent forecast to a total of $35 billion through 2025. People briefed on the plans told Reuters that the spending will include two additional U.S. battery plants.\nJohnson & Johnson(JNJ) – The Food and Drug Administration cleared 15 million more doses of J&J's Covid-19 vaccine that had been produced at a Baltimore plant run byEmergent Biosolutions(EBS). That brings the total of cleared doses to 25 million. Earlier, the FDA had rejected 60 million doses produced at that plant, saying Emergent hadn't taken proper precautions to prevent cross-contamination with another production line that was producingAstraZeneca's(AZN) Covid vaccine.\nSouthwest Airlines(LUV) – Southwest suffered its second computer glitch in 24 hoursTuesday, with a system outage leading to the cancellation of about 500 flights and delaying many others.\nDish Network(DISH) – The satellite TV company was upgraded to \"buy\" from \"hold\" at Pivotal Research, which cited the potential for Dish's 5G wireless network. Dish rose 1.7% in the premarket.\nApollo Global(APO) – Apollo sold textbook and educational technology company McGraw Hill to private-equity firm Platinum Equity for $4.5 billion.\nRegeneron(REGN) – The drugmaker'sCovid-19 antibody cocktailreduced deaths in patients who could not mount their own antibody response, according to a newly published British study.\nSoFi Technologies(SOFI) – The financial services platform was rated \"buy\" in new coverage at Rosenblatt Securities, noting SoFi's \"powerful\" cost advantage over legacy banks. SoFi shares rose 2.1% in the premarket.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"KIN":0.9,"ORCL":0.9}},"isVote":1,"tweetType":1,"viewCount":168,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187640213,"gmtCreate":1623753304332,"gmtModify":1634029017457,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187640213","repostId":"2143735244","repostType":4,"isVote":1,"tweetType":1,"viewCount":378,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187656548,"gmtCreate":1623753177184,"gmtModify":1634029021993,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Good to dip your toes into a little bit of crypto.&nbsp;","listText":"Good to dip your toes into a little bit of crypto.&nbsp;","text":"Good to dip your toes into a little bit of crypto.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187656548","repostId":"2143735752","repostType":4,"isVote":1,"tweetType":1,"viewCount":125,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}